Valion Bio (VBIO) Research & Development (2021 - 2025)
Valion Bio (VBIO) posted quarterly Research & Development of $858000.0 for Q3 2025, up 266.67% year-over-year from $234000.0 in Q3 2024, and up 101.41% quarter-over-quarter from $426000.0 in Q2 2025.
Valion Bio (VBIO) Research & Development (2021 - 2025) Analysis & Trends
Valion Bio's Research & Development history runs 5 years deep, the most recent figure standing at $858000.0 for Q3 2025.
- In Q3 2025, Research & Development rose 266.67% year-over-year to $858000.0; the TTM figure through Sep 2025 stood at $1.7 million (up 19.2% YoY), while the FY2024 annual figure was $1.2 million, down 28.28% from the prior year.
- Research & Development for Q3 2025 stood at $858000.0, up from $426000.0 in the prior quarter.
- The five-year high for Research & Development was $1.2 million in Q4 2021, with the low at $175000.0 in Q3 2021.
- The 5-year median for Research & Development is $401000.0 (2022), against an average of $426842.1.
- Peak annual rise in Research & Development reached 266.67% in 2025, while the deepest fall reached 64.55% in 2025.
- Valion Bio's Research & Development stood at $1.2 million in 2021, then plunged by 64.4% to $435000.0 in 2022, then retreated by 17.24% to $360000.0 in 2023, then sank by 42.5% to $207000.0 in 2024, then surged by 314.49% to $858000.0 in 2025.
- Business Quant data shows VBIO's Research & Development at $858000.0 in Q3 2025, $426000.0 in Q2 2025, and $179000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 97.90 Mn |
| 10 | Valion Bio | 423,175.64 | -1.78 Mn | -45,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 858,000.00 |
| Jun 30, 2025 | 426,000.00 |
| Mar 31, 2025 | 179,000.00 |
| Dec 31, 2024 | 207,000.00 |
| Sep 30, 2024 | 234,000.00 |
| Jun 30, 2024 | 302,000.00 |
| Mar 31, 2024 | 505,000.00 |
| Dec 31, 2023 | 360,000.00 |
| Sep 30, 2023 | 337,000.00 |
| Jun 30, 2023 | 452,000.00 |
| Mar 31, 2023 | 490,000.00 |
| Dec 31, 2022 | 435,000.00 |
| Sep 30, 2022 | 487,000.00 |
| Jun 30, 2022 | 497,000.00 |
| Mar 31, 2022 | 401,000.00 |
| Dec 31, 2021 | 1.22 Mn |
| Sep 30, 2021 | 175,000.00 |
| Jun 30, 2021 | 345,000.00 |
| Mar 31, 2021 | 198,000.00 |